Jiaying Guo
Immunology and Microbiology · Indiana University
Publications
51
Citations
563
Est. group size
—
Recurring co-author estimate
Active years
23
Publishing since 2004
Jiaying Guo's work centers on clinical research methods and health outcomes, including the statistical design of clinical trials (such as adaptive and biomarker-based trial designs), systematic reviews of treatment guidelines, and studies of drug effectiveness and access. Publications span disease areas including cystic fibrosis, psoriasis, amyotrophic lateral sclerosis (ALS), and inflammatory/arthritic conditions, often examining treatment outcomes, medication access, and health economics.
Publication activity has been steady, averaging about five papers per year over the last five years with consistent output through 2026.
Generated by claude-opus-4-8 from public bibliographic data · Jul 9, 2026
Typically publishes in teams of ~7 · 0% small-team papers (≤3 authors) · across 24 venues
- Evaluating ALSFRS-R as an indicator of disease milestones and functional independence: An observational study of US neurologists and their patients with amyotrophic lateral sclerosis
Journal of the Neurological Sciences · 2026
- An Adaptive Biomarker-based Umbrella Trial Design Using Bayesian Latent Class Model
Figshare · 2026
- An Adaptive Biomarker-Based Umbrella Trial Design Using Bayesian Latent Class Model
Figshare · 2026
- An Adaptive Biomarker-Based Umbrella Trial Design Using Bayesian Latent Class Model
Statistics in Biopharmaceutical Research · 2026
- An Adaptive Biomarker-Based Umbrella Trial Design Using Bayesian Latent Class Model
Figshare · 2026
- Evaluation of clinical practice guidelines on treatment of cystic fibrosis: A systematic review
Journal of Cystic Fibrosis · 2025
- Salidroside: A Potential Drug Candidate to Treat Rheumatoid Arthritis
Molecules · 2025
- SFP-Net: Scatter-feature-perception network for underwater image enhancement
Displays · 2025
- Ferroptosis inhibition mitigates glyphosate-induced inflammation and blood–milk barrier disruption in bovine mammary epithelial cells
Food and Chemical Toxicology · 2025
- WS01.05Time to reimbursement for elexacaftor/tezacaftor/ivacaftor across countries in the ECFS patient registry
Journal of Cystic Fibrosis · 2025
- 404 Global disparities in time from marketing authorization to reimbursement for elexacaftor/tezacaftor/ivacaftor
Journal of Cystic Fibrosis · 2025
- Nifuroxazide Improves Inflammation and Septic Shock by Suppressing C/EBPβ Signaling Pathway and Macrophage Migration
Research Square · 2024
- Development and Testing of a Multi-Component Intervention to Improve Medication Literacy in Glaucoma Patients
Patient Preference and Adherence · 2024
- Evaluation of Clinical Practice Guidelines on Treatment of Cystic Fibrosis: A Systematic Review
SSRN Electronic Journal · 2024
- 421 Research and development expenditure for CFTR modulators versus revenues after marketing: striking the balance?
Journal of Cystic Fibrosis · 2024
- Journal of the American Academy of Dermatology×9
- Journal of Cystic Fibrosis×4
- PubMed×3
- Advances in Therapy×3
- Figshare×3
- Kelly A. Reynolds
Immunology and Microbiology · University of Michigan
- Terri Ridenour
Immunology and Microbiology · University of Michigan
- Enze Xing
Immunology and Microbiology · University of Michigan
- Allison C. Billi
Immunology and Microbiology · University of Michigan
- Charles N. Ellis
Immunology and Microbiology · University of Michigan
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 27, 2026.
Claim or correct this profile